Michael Narachi, President and CEO at Orexigen Therapeutics, Inc. (OREX), sold 225,000 shares at $5.66 ($1.3M) on 2012-06-28, disclosed to the SEC on 2012-06-29.
Scheduled sale ($1.3M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $5.66 | 100,000 | $566K | 42.7% |
| 2 | $6.08 | 125,000 | $760K | 57.3% |
| Total | $5.89 avg | 225,000 | $1.3M | 100% |
| Filing → |
| OREX | SELL | 2012-07-19 | $1.1M | — | Filing → |
| OREX | SELL | 2012-07-13 | $1.0M | — | Filing → |
| AMAG | BUY | 2012-05-29 | $27K | — | Filing → |